The SOLACE-AU Clinical Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

Also called NCT01675596

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 199 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01675596
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01675596. Allocation not applicable; no masking; primary purpose treatment. Start 2012-04 (actual); primary completion 2016-02 (actual). Results posted on 2019-04-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The SOLACE-AU Clinical Trial
Acronym
SOLACE-AU
Condition
Severe, Symptomatic Aortic Stenosis
Intervention (Device)
TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Lead sponsor
Edwards Lifesciences (class: industry)
Collaborator
Pacific Clinical Research Group (class: other)

Record details

Record id
cardio:ct-nct01675596
Content hash
ad0fde0cf6e9009b601eab867875f49e6283e16255eb099c020d02d185493c8e